An anti-TROP-2 antibody-drug conjugate binds TROP-2, is internalized, the cleavable linker is processed, and the exatecan-derived topoisomerase I inhibitor (SHR9265) is released inside the cell, inhibiting topo I and causing DNA damage, replication arrest, and apoptosis of TROP-2-expressing cells.